Left Ventricular Assist Device Therapy Comes of Age at the Brigham

The Brigham is giving advanced heart failure patients a new option that parallels the life prolongation of heart transplantation: implantation of a fully magnetically levitated left ventricular assist device. Mandeep R. Mehra, MD, and Akinobu Itoh, MD, PhD, are at the forefront of these efforts.


SGLT2 Inhibitors Should Be Considered Foundational Therapy in All Patients With Heart Failure

Young doctor pointing to illustration of heart anatomy to show a patient sitting in office

Scott D. Solomon, MD, director of the Clinical Trials Outcomes Center at Brigham and Women’s Hospital, and colleagues have concluded that SGLT2 inhibitors should be considered adjunctive therapy for all patients with heart failure, regardless of ejection fraction or care setting.


Dapagliflozin Safe and Effective After Hospitalization for Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Male patient lying in hospital bed smiling up at doctor standing bedside

In a prespecified secondary analysis of the DELIVER trial, Scott D. Solomon, MD, at Brigham and Women’s Hospital, and colleagues found that starting dapagliflozin during or shortly after hospitalization for HF is safe and effective for patients with mildly reduced or preserved ejection fraction.


Prospective RCT Finds Full-Dose Anticoagulation Better Than Standard Dose in Severe COVID-19

Female patient on respirator in hospital bed with two doctors monitoring

In COVID-PACT, a 2×2 factorial, randomized, controlled trial that enrolled critically ill patients with COVID-19, researchers at Brigham and Women’s Hospital determined full-dose anticoagulation was superior to standard-dose prophylaxis in reducing the proportion of patients experiencing a thrombotic event.


Brigham Cardiovascular Experts Attend AHA Scientific Sessions 2022

Audience seated looking up at male presenter at a conference

On November 5—7, 2022, experts from the Brigham’s Heart and Vascular Center will join thousands of colleagues in raising awareness and improving cardiovascular health at this year’s American Heart Association (AHA) Scientific Sessions.


Hospitalization for Any Cause Increases Risk of Postdischarge Mortality in Patients With HFpEF

Older woman with pink shirt holding her chest, heart failure concept

Brigham researchers confirmed that non-heart failure (HF) hospitalizations are burdensome for patients who have HF with preserved ejection fraction (HFpEF), who tend to have more noncardiac comorbidities than patients who have HF with reduced ejection fraction.


Study Finds Drug Benefits Heart Failure Patients With Normal Ejection Fraction

Cardiologist showing patient an anatomical model of human heart, sitting at desk

A team led by Brigham investigators has reported findings from a study looking at whether heart failure patients with mildly reduced or preserved ejection fraction could benefit from treatment with the sodium-glucose cotransporter 2 inhibitor dapagliflozin. First author Scott David Solomon, MD, shares his perspective.


Genotype Influences Heart Failure Pathways

RNA macromolecule skeletal formula, molecular structure of RNA single strand

An international research team co-led by Christine E. Seidman, MD, found that molecular and cellular mechanisms of heart failure in patients with dilated cardiomyopathy or arrhythmogenic cardiomyopathy were determined by the specific gene variant each individual carried.


STEMI Rare in Patients Hospitalized With COVID-19, but Prognosis Is Poor

Close up of white graph paper from electrocardiogram showing ST-elevation

Researchers at Brigham and Women’s Hospital recently completed the first large multicenter study of the incidence of ST-segment–elevation myocardial infarction (STEMI) as a complication of COVID-19. STEMI was rare in 0.35% of patients but was associated with poor in-hospital outcomes and high mortality.